These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 1471191)

  • 1. Difficulties in conceiving and applying guidelines for the safety evaluation of biotechnologically-produced drugs: some examples.
    Claude JR
    Toxicol Lett; 1992 Dec; 64-65 Spec No():349-55. PubMed ID: 1471191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond.
    Serabian MA; Pilaro AM
    Toxicol Pathol; 1999; 27(1):27-31. PubMed ID: 10367669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reproductive toxicology guidelines: comparison and application.
    Beltrame D; Mazué G
    Ann Ist Super Sanita; 1993; 29(1):3-14. PubMed ID: 8129269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding and applying regulatory guidance on the nonclinical development of biotechnology-derived pharmaceuticals.
    Snodin DJ; Ryle PR
    BioDrugs; 2006; 20(1):25-52. PubMed ID: 16573349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonclinical safety evaluation of biotechnologically derived pharmaceuticals.
    Dempster AM
    Biotechnol Annu Rev; 2000; 5():221-58. PubMed ID: 10875002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-clinical combination toxicology studies: strategy, examples and future perspective.
    Sacaan A; Hashida SN; Khan NK
    J Toxicol Sci; 2020; 45(7):365-371. PubMed ID: 32612005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Critical aspects regarding the application of GPL principles to new compounds such as biotechnology products.
    Brunetti MM
    Ann Ist Super Sanita; 2008; 44(4):385-9. PubMed ID: 19352001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of biotechnology products for therapeutic use.
    Sims J
    Toxicol Lett; 2001 Mar; 120(1-3):59-66. PubMed ID: 11323162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety evaluation of biological and biotechnology-derived medicines.
    Dayan AD
    Toxicology; 1995 Dec; 105(1):59-68. PubMed ID: 8638284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The international harmonisation of guidelines in the future: a viewpoint from the industry.
    Ekman L
    Toxicol Lett; 1998 Dec; 102-103():551-5. PubMed ID: 10022311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Harmonization of guidelines for toxicity testing of pharmaceuticals by 1992.
    Speid LH; Lumley CE; Walker SR
    Regul Toxicol Pharmacol; 1990 Oct; 12(2):179-211. PubMed ID: 2259757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternative methods to safety studies in experimental animals: role in the risk assessment of chemicals under the new European Chemicals Legislation (REACH).
    Lilienblum W; Dekant W; Foth H; Gebel T; Hengstler JG; Kahl R; Kramer PJ; Schweinfurth H; Wollin KM
    Arch Toxicol; 2008 Apr; 82(4):211-36. PubMed ID: 18322675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety assessment of biopharmaceuticals: Japanese perspective on ICH S6 guideline maintenance.
    Nakazawa T; Kurokawa M; Kimura K; Wakata A; Hisada S; Inoue T; Sagami F; Heidel SM; Kawakami K; Shinoda K; Onodera H; Kumagai Y; Ohno Y; Kawamura N; Yamazaki T; Inoue T
    J Toxicol Sci; 2008 Aug; 33(3):277-82. PubMed ID: 18670158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FIFRA Subdivision F testing Guidelines: are these tests adequate to detect potential hormonal activity for crop protection chemicals? Federal Insecticide, Fungicide, and Rodenticide Act.
    Stevens JT; Tobia A; Lamb JC; Tellone C; O'Neal F
    J Toxicol Environ Health; 1997 Apr; 50(5):415-31. PubMed ID: 9140462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An analysis of pharmaceutical experience with decades of rat carcinogenicity testing: support for a proposal to modify current regulatory guidelines.
    Sistare FD; Morton D; Alden C; Christensen J; Keller D; Jonghe SD; Storer RD; Reddy MV; Kraynak A; Trela B; Bienvenu JG; Bjurström S; Bosmans V; Brewster D; Colman K; Dominick M; Evans J; Hailey JR; Kinter L; Liu M; Mahrt C; Marien D; Myer J; Perry R; Potenta D; Roth A; Sherratt P; Singer T; Slim R; Soper K; Fransson-Steen R; Stoltz J; Turner O; Turnquist S; van Heerden M; Woicke J; DeGeorge JJ
    Toxicol Pathol; 2011 Jun; 39(4):716-44. PubMed ID: 21666103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 10th annual meeting of the Safety Pharmacology Society: an overview.
    Cavero I
    Expert Opin Drug Saf; 2011 Mar; 10(2):319-33. PubMed ID: 21314442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current guidelines for the preclinical safety assessment of therapeutic proteins.
    Bass R; Kleeberg U; Schröder H; Scheibner E
    Toxicol Lett; 1992 Dec; 64-65 Spec No():339-47. PubMed ID: 1471190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicology in the drug discovery and development process.
    Dorato MA; Buckley LA
    Curr Protoc Pharmacol; 2006 Apr; Chapter 10():Unit10.3. PubMed ID: 22294168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.